Delivery Order SPE2DB20D7059-SPE2DB25FQMT4
- Not listed
- The Defense Logistics Agency awarded a $3,725.44 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Letrozole 2.5 mg tablets (90-count packages). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 29, 2025, to be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Letrozole is an aromatase inhibitor commonly used in hormone therapy for breast cancer treatment, reflecting the Defense Logistics...
- The Defense Logistics Agency awarded a $3,172.86 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Letrozole 2.5 mg tablets (90-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 29, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and represents a child delivery order under the company's larger...
- The Defense Logistics Agency (DLA) awarded a $1,145.15 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Letrozole 2.5 mg tablets in quantities of 30. The contract, which is a firm fixed price delivery order with no set-aside designation, is scheduled for completion by July 28, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award represents a competitive procurement action and reflects AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a delivery order valued at $6,117.34 to AmerisourceBergen Drug Corp for the supply of Letrozole 2.5 mg tablets in a quantity of 90s. This firm fixed-price delivery order, awarded on August 5, 2025, with an ultimate completion date of August 6, 2025, was competitively awarded with no set-aside designation. The products will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Letrozole is an aromatase...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for Letrozole 2.5mg (90-count supply) valued at $6,490.08 under a firm fixed price contract type. The award was made on July 24, 2025, with an ultimate completion date of the same day, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in the same...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Letrozole 2.5 mg tablets in quantities of 90 units, valued at $1,403.88. This firm fixed price delivery order, which is not set-aside and was competitively awarded, is set for ultimate completion on July 29, 2025. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government, with performance occurring at the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Letrozole 2.5 mg tablets (90-count) under a firm fixed-price contract valued at $1,476.58. The order was competitively awarded without set-aside designation and is scheduled for completion by August 12, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a continuation of the company's...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Letrozole 2.5 mg tablets in quantities of 90 units. This contract, valued at $1,802.80 with a firm fixed price structure, represents a non-set-aside, competitively awarded procurement supporting federal medical supply needs. The order is scheduled for completion by July 29, 2025, and will be fulfilled from the contractor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Letrozole 2.5 mg tablets (90-count units) with a ceiling value of $2,763.95 and an ultimate completion date of August 6, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and is classified as a delivery order, indicating it falls under a larger indefinite delivery contract vehicle. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Letrozole 2.5 mg tablets in quantities of 90 units. This non-set-aside, competitively awarded contract has a ceiling value of $1,528.52 and is structured as a firm fixed-price delivery order with an ultimate completion date of July 21, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a discrete...
- SPE2DB20D7059Indefinite Delivery Contract
- SPE2DB20D7059-SPE2DB25FQMT4Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, valued at $1,081.68, for the supply of Letrozole 2.5 mg tablets in a quantity of 90 units. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order with an ultimate completion date of August 6, 2025. The award was issued on August 5, 2025, with performance to be executed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. Letrozole is a hormone therapy medication commonly used in the treatment of breast cancer, and this order fulfills federal medical supply requirements within the Department of Defense healthcare system. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 blanket purchase agreement running through December 2026. AmerisourceBergen serves as a critical pharmaceutical prime vendor for the Defense Logistics Agency, supplying a comprehensive range of medications and medical commodities across multiple therapeutic domains to support military and veteran healthcare programs. The company's established relationship with DLA, demonstrated through numerous competitively awarded contracts and its substantial IDC vehicle, enables efficient fulfillment of federal pharmaceutical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/5/25 |